Objectif Platinum-based chemotherapy is the primary therapeutic intervention for over 500,000 patients per year in the EU. Although some patients are cured by this type of chemotherapy, as many as 75% of lung cancer patients and 60% of bladder cancer patients show no benefit and could be more appropriately given alternative treatments, and therefore over €4bn annually is wasted on unnecessary treatments. There is a need for a rapid, accurate test to distinguish those patients who are likely to respond to chemotherapy and those who are not. Accelerated Medical Diagnostics aim to personalise chemotherapy for cancer patients through their own developed PlatinDx assay, which can be used to identify those patients which are appropriate for platinum-based chemotherapy. Cancer patients are given a microdose (1% of the therapeutic dose) of a platinum-based drug, followed by quantitation of drug-DNA adducts in biopsy tissye using accelerator mass spectrometry (AMS). Levels of drug-DNA damage are measured by AMS in white blood cells and tumor biopsy tissue, which are used as a predictor of therapeutic response. Within the innovation project Accelerated Medical Diagnoistics intend to: gain medical certification within the EU; run a scaled up clinical trial to gain significant results; and adress the EU market and launch their service in the EU. Champ scientifique medical and health sciencesclinical medicineoncologybladder cancernatural scienceschemical sciencesanalytical chemistrymass spectrometry Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Appel à propositions H2020-SMEInst-2014-2015 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2014 Régime de financement SME-1 - SME instrument phase 1 Coordinateur ACCELERATED MEDICAL DIAGNOSTICS LTD Contribution nette de l'UE € 50 000,00 Adresse 72 Great Suffolk Street SE1 0BL London Royaume-Uni Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région London Inner London — East Lewisham and Southwark Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00 Participants (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire HAMMERSMITH MEDICINES RESEARCH LTD Royaume-Uni Contribution nette de l'UE € 0,00 Adresse 44 CUMBERLAND AVENUE NW10 7EW London Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région London Outer London — West and North West Brent Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total Aucune donnée
